Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

01-12-2020 | Colorectal Cancer | Primary research

Overexpression of SAPCD2 correlates with proliferation and invasion of colorectal carcinoma cells

Authors: Yage Luo, Lili Wang, Wenwen Ran, Guangqi Li, Yujing Xiao, Xiaonan Wang, Han Zhao, Xiaoming Xing

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Suppressor anaphase-promoting complex domain containing 2 (SAPCD2) is a novel gene playing important roles in the initiation, invasion, and metastasis of several malignancies. However, its role in colorectal carcinoma (CRC) still remains unclear.

Method

In this study, we investigated the expression and biological function of SAPCD2 in CRC. Immunohistochemistry (IHC) for SAPCD2 was performed in 410 pairs of CRC specimens and corresponding normal epithelial tissues, and in 50 adenoma tissues. Clinical pathological factors were analyzed in relation to the expression of SAPCD2. The biological functions of SAPCD2 in CRC cells and its effect on cell cycle were investigated in vitro and in vivo through gain/loss-of-function approaches.

Results

IHC showed that SAPCD2 expression was significantly higher in CRC tissues compared to adenoma and normal epithelium tissues and was correlated with tumor location (p = 0.018). SAPCD2 significantly promoted cell proliferation, migration, and invasion both in vitro and in vivo (p < 0.05). In addition, SAPCD2 knockdown in CRC cells was associated with reduced G1/S transition, while overexpression caused G2/M phase arrest (p < 0.05).

Conclusions

In sum, SAPCD2 is overexpressed in CRC tissues and plays a critical role in CRC progression. Therefore, it might represent a promising therapeutic target for CRC treatment.
Literature
1.
2.
Xu X, Li W, Fan X, Liang Y, Zhao M, Zhang J, et al. Identification and characterization of a novel p42.3 gene as tumor-specific and mitosis phase-dependent expression in gastric cancer. Oncogene. 2007;26(52):7371–9.PubMedCrossRef
3.
Zhang JL, Lu CL, Shang ZG, Xing R, Shi L, Lv YY. p42.3 gene expression in gastric cancer cell and its protein regulatory network analysis. Theor Biol Med Model. 2012;9(1):53–62.PubMedPubMedCentralCrossRef
4.
Hao Y, Fan T, Nan K. Optimization and corroboration of the regulatory pathway of p42.3 protein in the pathogenesis of gastric carcinoma. Comput Math Method Med. 2015;2015: 683617–79.
5.
Liu X, Hao Y, Fan T, Nan K. Application of intelligent algorithm in the optimization of novel protein regulatory pathway: mechanism of action of gastric carcinoma protein p42.3. J Cancer Res Ther. 2016;12(2):650–6.PubMedCrossRef
6.
Sun W, Dong WW, Mao LL, Li WM, Cui JT, Xing R, et al. Overexpression of p42.3 promotes cell growth and tumorigenicity in hepatocellular carcinoma. World J Gastroenterol. 2013;19(19):2913–20.PubMedPubMedCentralCrossRef
7.
Liu H, Zhu M, Li Z, Wang Y, Xing R, Lu Y, et al. Depletion of p42.3 gene inhibits proliferation and invasion in melanoma cells. J Cancer Res Clin Oncol. 2017;143(4):639–48.PubMedCrossRef
8.
Wan W, Xu X, Jia G, Li W, Wang J, Ren T, et al. Differential expression of p42.3 in low- and high-grade gliomas. World J Surg Oncol. 2014;12(1):185–92.PubMedPubMedCentralCrossRef
9.
Li P, Cao WJ, Mao LL, Huang H, Zheng JN, Pei DS. p42.3 promotes cell proliferation and invasion in human renal-cell carcinoma. Int J Clin Exp Med. 2014;7(12):4959–66.PubMedPubMedCentral
10.
Weng YR, Yu YN, Ren LL, Cui Y, Lu YY, Chen HY, et al. Role of C9orf140 in the promotion of colorectal cancer progression and mechanisms of its upregulation via activation of STAT5, beta-catenin and EZH2. Carcinogenesis. 2014;35(6):1389–98.PubMedCrossRef
11.
Zhou X, Xing X, Zhang S, Liu L, Wang C, Li L, et al. Glucose-regulated protein 78 contributes to the proliferation and tumorigenesis of human colorectal carcinoma via AKT and ERK pathways. Oncol Rep. 2016;36(5):2723–30.PubMedCrossRef
12.
Cao WJ, Du WQ, Mao LL, Zheng JN, Pei DS. Overexpression of p42.3 promotes cell proliferation, migration, and invasion in human gastric cancer cells. Tumor Biol. 2016;37(9):12805–12.CrossRef
13.
Cao WJ, Mao LL, Zheng JN, Pei DS. p42.3:an abductor of cell cycle. AntiCancer Agent Med Chem. 2015;15(2):157–62.CrossRef
14.
Yuan XS, Zhang Y, Guan XY, Dong B, Zhao M, Mao LL, et al. p42.3: a promising biomarker for the progression and prognosis of human colorectal cancer. J Cancer Res Clin Oncol. 2013;139(7):1211–20.PubMedCrossRef
15.
Chen P, Cui Y, Fu QY, Lu YY, Fang JY, Chen XY. Positive relationship between p42.3 gene and inflammation in chronic non-atrophic gastritis. J Dig Dis. 2015;16(10):568–74.PubMedCrossRef
16.
Hill MJ, Morson BC, Bussey HJ. Aetiology of adenoma–carcinoma sequence in large bowel. Lancet. 1978;8(58):245–7.CrossRef
17.
Risio M. The natural history of colorectal adenomas and early cancer. Pathologe. 2012;33(S2):206–10.PubMedCrossRef
18.
Cui Y, Su WY, Xing J, Wang YC, Wang P, Chen XY, et al. MiR-29a inhibits cell proliferation and induces cell cycle arrest through the downregulation of p42.3 in human gastric cancer. PloS One. 2011;6(10):e25872–9.PubMedPubMedCentralCrossRef
19.
Mao L, Sun W, Li W, Cui J, Zhang J, Xing R, et al. Cell cycle-dependent expression of p42.3 promotes mitotic progression in malignant transformed cells. Mol Carcinog. 2014;53(5):337–48.PubMedCrossRef
20.
Schwartz G, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 2005;23(36):9408–21.PubMedCrossRef
21.
22.
23.
Golan A, Pick E, Tsvetkov L, Nadler Y, Kluger H, Stern DF. Centrosomal Chk2 in DNA damage responses and cell cycle progression. Cell Cycle. 2010;9(13):2647–56.PubMedPubMedCentralCrossRef
24.
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66.PubMedCrossRef
25.
26.
De CB, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–110.CrossRef
27.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial–mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.PubMedCrossRef
28.
Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J. 2006;396(2):201–14.PubMedPubMedCentralCrossRef
29.
Grace A, Butler D, Gallagher M, Al-Agha R, Xin Y, Leader M, et al. APC gene expression in gastric carcinoma: an immunohistochemical study. Appl Immunohistochem Mol Morphol. 2002;10(3):221–4.PubMed
30.
He TC, Sparks AB, Rago C, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–12.PubMedCrossRef
31.
Hutchins JR, Toyoda Y, Hegemann B, Peters JM. Systematic analysis of human protein complexes identifies chromosome segregation proteins. Science. 2010;328(5978):593–9.PubMedPubMedCentralCrossRef
Metadata
Title
Overexpression of SAPCD2 correlates with proliferation and invasion of colorectal carcinoma cells
Authors
Yage Luo
Lili Wang
Wenwen Ran
Guangqi Li
Yujing Xiao
Xiaonan Wang
Han Zhao
Xiaoming Xing
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-1121-6

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Assessing immune infiltration and the tumor microenvironment for the diagnosis and prognosis of sarcoma

Primary research

Circular RNA circPLK1 promotes breast cancer cell proliferation, migration and invasion by regulating miR-4500/IGF1 axis

Primary research

TRIP6 enhances stemness property of breast cancer cells through activation of Wnt/β-catenin

Primary research

Joint analysis of lncRNA m6A methylome and lncRNA/mRNA expression profiles in gastric cancer

Primary research

Adipocytes promote tumor progression and induce PD-L1 expression via TNF-α/IL-6 signaling

Primary research

Circ_0000140 restrains the proliferation, metastasis and glycolysis metabolism of oral squamous cell carcinoma through upregulating CDC73 via sponging miR-182-5p
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits